Amylyx Launches $350M Stock Offering Days After Positive Phase 3 Data
AMLX has more than doubled off its 52-week low of $7.63 on elevated volume (11× avg).
Summary
Amylyx is raising $350 million in a public offering, with underwriters holding a 30-day option for another $52.5 million. The raise comes just hours after the company announced positive Phase 3 LUCIDITY results for avexitide, which sent the stock near its 52-week high. The offering will dilute existing shareholders by roughly 9% at the current $35.075 price, but the company is capitalizing on the data-driven rally to fund pre-commercial manufacturing and R&D. This follows a Q2 miss and insider selling plans disclosed earlier this month, suggesting management is moving quickly to secure cash while the window is open. The offering is subject to market conditions and may not be completed on these terms.
At the time of this announcement, AMLX was trading at $35.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9B. The 52-week trading range was $7.63 to $35.39. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: BusinessWire.